Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP9 | P14780 | 6/20 | 0.46 |
| ▸ | MMP1 | P03956 | 5/20 | 0.46 |
| ▸ | MMP3 | P08254 | 5/20 | 0.46 |
| ▸ | MMP14 | P50281 | 5/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 8/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220240 | 0.89 | GPR88 (0.45) | GPR88AOC3GPR139ATMMEN1 | |
| SCHEMBL3214499 | 0.85 | GPR139 (0.54) | GPR139ATMMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3207851 | 0.84 | MMP2 (0.46) | MMP2MMP9MMP1MMP3MMP14 | |
| SCHEMBL16349034 | 0.80 | NPC1 (0.41) | MMP2MMP9MMP1MMP3MMP14 | |
| SCHEMBL13770905 | 0.80 | GPR88 (0.45) | GPR88AOC3GPR139ATMMEN1 | |
| SCHEMBL3221057 | 0.79 | GPR88 (0.45) | GPR88MEN1KMT2A | |
| SCHEMBL4781054 | 0.79 | GPR88 (0.45) | GPR88MEN1KMT2A | |
| SCHEMBL3222168 | 0.78 | GPR88 (0.40) | GPR88 | |
| SCHEMBL4785164 | 0.78 | GPR88 (0.40) | GPR88 | |
| SCHEMBL10174287 | 0.78 | CTSD (0.41) | MMP2MMP9MMP1MMP3MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | ABBVIE INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8497275-B2 | HCV protease inhibitors and uses thereof | ABBVIE INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | SERPINB1, PEPD, PREP | MMP2 118/4885MMP9 250/4885MMP1 251/4885 |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, PEPD, PREP | MMP2 118/4885MMP9 250/4885MMP1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.